Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

4.340 +0.530 (+13.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
From Lantern Pharma Inc.
Via Business Wire
EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial
Lantern Pharma's LP-184 advances to Phase 1b/2 trial in TNBC after FDA clearance, adding to its Fast Track and Rare Pediatric Disease designations. 
Via Benzinga
Exposures Product Safety
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
From Lantern Pharma Inc.
Via Business Wire
Preview: Lantern Pharma's Earnings
Via Benzinga
Earnings Scheduled For March 27, 2025
Via Benzinga
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma Inc. (LTRN) Expands HARMONIC™ Trial to Asia with First Patient Dosed in Taiwan
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Host & Participate in Two Public Webinars During October
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
From Lantern Pharma Inc.
Via Business Wire
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024
LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
From Lantern Pharma
Via Business Wire
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
From Lantern Pharma
Via Business Wire
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
From Lantern Pharma
Via Business Wire
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.